{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:30:05Z","timestamp":1778553005856,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Ministry of Health, Labour, and Welfare of Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00403-017-1786-4","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T16:09:02Z","timestamp":1508170142000},"page":"833-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis"],"prefix":"10.1007","volume":"309","author":[{"given":"Takashi","family":"Taniguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenshiro","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Saigusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Ichimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Kadono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-9778","authenticated-orcid":false,"given":"Yoshihide","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"issue":"Suppl 3","key":"1786_CR1","first-page":"iii3","volume":"48","author":"DJ Abraham","year":"2009","unstructured":"Abraham DJ, Krieg T, Distler J, Distler O (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48(Suppl 3):iii3\u2013iii7","journal-title":"Rheumatology (Oxford)"},{"key":"1786_CR2","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/rheumatology\/keu479","volume":"54","author":"K Akamata","year":"2015","unstructured":"Akamata K, Asano Y, Taniguchi T et al (2015) Increased expression of chemerin in endothelial cells due to Fli1 deficiency may contribute to the development of digital ulcers in systemic sclerosis. Rheumatology (Oxford) 54:1308\u20131316","journal-title":"Rheumatology (Oxford)"},{"key":"1786_CR3","doi-asserted-by":"crossref","first-page":"34672","DOI":"10.1074\/jbc.M703907200","volume":"282","author":"Y Asano","year":"2007","unstructured":"Asano Y, Czuwara J, Trojanowska M (2007) Transforming growth factor-\u03b2 regulates DNA binding activity of transcription factor Fli1 by p300\/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 282:34672\u201334683","journal-title":"J Biol Chem"},{"key":"1786_CR4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1346-8138.2009.00758.x","volume":"37","author":"Y Asano","year":"2010","unstructured":"Asano Y (2010) Future treatments in systemic sclerosis. J Dermatol 37:54\u201370","journal-title":"J Dermatol"},{"key":"1786_CR5","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2353\/ajpath.2010.090593","volume":"176","author":"Y Asano","year":"2010","unstructured":"Asano Y, Stawski L, Hant F et al (2010) Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 176:1983\u20131998","journal-title":"Am J Pathol"},{"key":"1786_CR6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.biocel.2015.06.004","volume":"67","author":"Y Asano","year":"2015","unstructured":"Asano Y (2015) Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis. Int J Biochem Cell Biol 67:86\u201391","journal-title":"Int J Biochem Cell Biol"},{"key":"1786_CR7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00281-015-0505-5","volume":"37","author":"Y Asano","year":"2015","unstructured":"Asano Y, Sato S (2015) Vasculopathy in scleroderma. Semin Immunopathol 37:489\u2013500","journal-title":"Semin Immunopathol"},{"key":"1786_CR8","first-page":"298","volume":"11","author":"J Ash","year":"2005","unstructured":"Ash J, McLeod DS, Lutty GA (2005) Transgenic expression of leukemia inhibitory factor (LIF) blocks normal vascular development but not pathological neovascularization in the eye. Mol Vis 11:298\u2013308","journal-title":"Mol Vis"},{"key":"1786_CR9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3349\/ymj.2011.52.1.113","volume":"52","author":"SJ Chung","year":"2011","unstructured":"Chung SJ, Kwon YJ, Park MC, Park YB, Lee SK (2011) The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. Yonsei Med J 52:113\u2013120","journal-title":"Yonsei Med J"},{"key":"1786_CR10","first-page":"1892","volume":"20","author":"PJ Clements","year":"1993","unstructured":"Clements PJ, Lachenbruch PA, Seibold JR et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892\u20131896","journal-title":"J Rheumatol"},{"key":"1786_CR11","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1073\/pnas.89.2.698","volume":"89","author":"N Ferrara","year":"1992","unstructured":"Ferrara N, Winer J, Henzel WJ (1992) Pituitary follicular cells secrete an inhibitor of aortic endothelial cell growth: identification as leukemia inhibitory factor. Proc Natl Acad Sci USA 89:698\u2013702","journal-title":"Proc Natl Acad Sci USA"},{"key":"1786_CR12","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/j.1460-2075.1987.tb02742.x","volume":"6","author":"DP Gearing","year":"1987","unstructured":"Gearing DP, Gough NM, King JA et al (1987) Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J 6:3995\u20134002","journal-title":"EMBO J"},{"key":"1786_CR13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0065-2776(08)60497-6","volume":"53","author":"DP Gearing","year":"1993","unstructured":"Gearing DP (1993) The leukemia inhibitory factor and its receptor. Adv Immunol 53:31\u201358","journal-title":"Adv Immunol"},{"key":"1786_CR14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1006\/dbio.1996.0167","volume":"177","author":"RL Gendron","year":"1996","unstructured":"Gendron RL, Tsai FY, Paradis H, Arceci RJ (1996) Induction of embryonic vasculogenesis by bFGF and LIF in vitro and in vivo. Dev Biol 177:332\u2013346","journal-title":"Dev Biol"},{"key":"1786_CR15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/08977199308991590","volume":"9","author":"NA Gillett","year":"1993","unstructured":"Gillett NA, Lowe D, Lu L, Chan C, Ferrara N (1993) Leukemia inhibitory factor expression in human carotid plaques: possible mechanism for inhibition of large vessel endothelial regrowth. Growth Factors 9:301\u2013305","journal-title":"Growth Factors"},{"key":"1786_CR16","first-page":"607","volume":"9","author":"R Guimbaud","year":"1998","unstructured":"Guimbaud R, Abitbol V, Bertrand V et al (1998) Leukemia inhibitory factor involvement in human ulcerative colitis and its potential role in malignant course. Eur Cytokine Netw 9:607\u2013612","journal-title":"Eur Cytokine Netw"},{"key":"1786_CR17","first-page":"308","volume":"25","author":"M Hasegawa","year":"1998","unstructured":"Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K (1998) Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 25:308\u2013313","journal-title":"J Rheumatol"},{"key":"1786_CR18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00403-013-1431-9","volume":"306","author":"Y Ichimura","year":"2014","unstructured":"Ichimura Y, Asano Y, Akamata K et al (2014) Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis. Arch Dermatol Res 306:331\u2013338","journal-title":"Arch Dermatol Res"},{"key":"1786_CR19","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrrheum.2011.132","volume":"7","author":"MJ Kaplan","year":"2011","unstructured":"Kaplan MJ (2011) Neutrophils in the pathogenesis and manifestations of SLE. Nat Rev Rheumatol 7:691\u2013699","journal-title":"Nat Rev Rheumatol"},{"key":"1786_CR20","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1172\/JCI117414","volume":"94","author":"AE Koch","year":"1994","unstructured":"Koch AE, Kunkel SL, Harlow LA et al (1994) Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 94:1012\u20131018","journal-title":"J Clin Invest"},{"key":"1786_CR21","first-page":"2393","volume":"118","author":"Y Kubota","year":"2008","unstructured":"Kubota Y, Hirashima M, Kishi K, Stewart CL, Suda T (2008) Leukemia inhibitory factor regulates microvessel density by modulating oxygen-dependent VEGF expression in mice. J Clin Invest 118:2393\u20132403","journal-title":"J Clin Invest"},{"key":"1786_CR22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/BOR.0b013e32832fd69e","volume":"21","author":"R Lafyatis","year":"2009","unstructured":"Lafyatis R, York M (2009) Innate immunity and inflammation in systemic sclerosis. Curr Opin Rheumatol 21:617\u2013622","journal-title":"Curr Opin Rheumatol"},{"key":"1786_CR23","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202\u2013205","journal-title":"J Rheumatol"},{"key":"1786_CR24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1468-3083.2011.04077.x","volume":"26","author":"Y Masui","year":"2012","unstructured":"Masui Y, Asano Y, Shibata S et al (2012) Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. J Eur Acad Dermatol Venereol 26:354\u2013360","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1786_CR25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/rheumatology\/ket010","volume":"52","author":"Y Masui","year":"2013","unstructured":"Masui Y, Asano Y, Shibata S et al (2013) A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response. Rheumatology (Oxford) 52:1239\u20131244","journal-title":"Rheumatology (Oxford)"},{"key":"1786_CR26","first-page":"275","volume":"33","author":"T Matsushita","year":"2006","unstructured":"Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33:275\u2013284","journal-title":"J Rheumatol"},{"key":"1786_CR27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/stemcells.21-1-5","volume":"21","author":"D Metcalf","year":"2003","unstructured":"Metcalf D (2003) The unsolved enigmas of leukemia inhibitory factor. Stem Cells 21:5\u201314","journal-title":"Stem Cells"},{"key":"1786_CR28","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1161\/01.ATV.14.8.1356","volume":"14","author":"CS Moran","year":"1994","unstructured":"Moran CS, Campbell JH, Simmons DL, Campbell GR (1994) Human leukemia inhibitory factor inhibits development of experimental atherosclerosis. Arterioscler Thromb 14:1356\u20131363","journal-title":"Arterioscler Thromb"},{"key":"1786_CR29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.1780350111","volume":"35","author":"BW Needleman","year":"1992","unstructured":"Needleman BW, Wigley FM, Stair RW (1992) Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor \u03b1, and interferon-\u03b3 levels in sera from patients with scleroderma. Arthritis Rheum 35:67\u201372","journal-title":"Arthritis Rheum"},{"key":"1786_CR30","doi-asserted-by":"crossref","first-page":"e32272","DOI":"10.1371\/journal.pone.0032272","volume":"7","author":"S Noda","year":"2012","unstructured":"Noda S, Asano Y, Akamata K et al (2012) A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. PLoS One 7:e32272","journal-title":"PLoS One"},{"key":"1786_CR31","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/rheumatology\/kes379","volume":"52","author":"S Noda","year":"2013","unstructured":"Noda S, Asano Y, Takahashi T et al (2013) Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. Rheumatology (Oxford) 52:790\u2013799","journal-title":"Rheumatology (Oxford)"},{"key":"1786_CR32","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1038\/ncomms6797","volume":"5","author":"S Noda","year":"2014","unstructured":"Noda S, Asano Y, Nishimura S et al (2014) Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis. Nat Commun 5:5797","journal-title":"Nat Commun"},{"key":"1786_CR33","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1038\/cti.2013.2","volume":"2","author":"S O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly S, Cant R, Ciechomska M, van Laar JM (2013) Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunology 2:e4","journal-title":"Clin Transl Immunology"},{"key":"1786_CR34","doi-asserted-by":"crossref","first-page":"9952","DOI":"10.1074\/jbc.M113.545822","volume":"289","author":"S O\u2019Reilly","year":"2014","unstructured":"O\u2019Reilly S, Ciechomska M, Cant R, van Laar JM (2014) Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-\u03b2 (TGF-\u03b2) signaling promoting SMAD3 activation and fibrosis via Gremlin protein. J Biol Chem 289:9952\u20139960","journal-title":"J Biol Chem"},{"key":"1786_CR35","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/0961203310370048","volume":"19","author":"G Obermoser","year":"2010","unstructured":"Obermoser G, Sontheimer RD, Zelger B (2010) Overview of common, rare and atypical manifestations of cutaneous lupus erythematosus and histopathological correlates. Lupus 19:1050\u20131070","journal-title":"Lupus"},{"issue":"Pt 1","key":"1786_CR36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1242\/jcs.108.1.73","volume":"108","author":"MS Pepper","year":"1995","unstructured":"Pepper MS, Ferrara N, Orci L, Montesano R (1995) Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro. J Cell Sci 108(Pt 1):73\u201383","journal-title":"J Cell Sci"},{"key":"1786_CR37","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0008-6363(02)00832-5","volume":"58","author":"BE Rolfe","year":"2003","unstructured":"Rolfe BE, Stamatiou S, World CJ et al (2003) Leukaemia inhibitory factor retards the progression of atherosclerosis. Cardiovasc Res 58:222\u2013230","journal-title":"Cardiovasc Res"},{"key":"1786_CR38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0923-1811(01)00128-1","volume":"27","author":"S Sato","year":"2001","unstructured":"Sato S, Hasegawa M, Takehara K (2001) Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 27:140\u2013146","journal-title":"J Dermatol Sci"},{"key":"1786_CR39","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.4049\/jimmunol.141.9.3055","volume":"141","author":"H Schainberg","year":"1988","unstructured":"Schainberg H, Borish L, King M, Rocklin RE, Rosenwasser LJ (1988) Leukocyte inhibitory factor stimulates neutrophil-endothelial cell adhesion. J Immunol 141:3055\u20133060","journal-title":"J Immunol"},{"key":"1786_CR40","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","volume":"49","author":"Y Shima","year":"2010","unstructured":"Shima Y, Kuwahara Y, Murota H et al (2010) The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 49:2408\u20132412","journal-title":"Rheumatology (Oxford)"},{"key":"1786_CR41","first-page":"17","volume":"13","author":"RA Stuart","year":"1995","unstructured":"Stuart RA, Littlewood AJ, Maddison PJ, Hall ND (1995) Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 13:17\u201322","journal-title":"Clin Exp Rheumatol"},{"key":"1786_CR42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1346-8138.2001.tb00104.x","volume":"28","author":"J Szepietowski","year":"2001","unstructured":"Szepietowski J, Walker C, Hunter JA, McKenzie RC (2001) Elevated leukaemia inhibitory factor (LIF) expression in lesional psoriatic skin: correlation with interleukin (IL)-8 expression. J Dermatol 28:115\u2013122","journal-title":"J Dermatol"},{"key":"1786_CR43","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1146\/annurev.immunol.15.1.797","volume":"15","author":"T Taga","year":"1997","unstructured":"Taga T, Kishimoto T (1997) Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797\u2013819","journal-title":"Annu Rev Immunol"},{"key":"1786_CR44","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1084\/jem.20160247","volume":"214","author":"T Takahashi","year":"2017","unstructured":"Takahashi T, Asano Y, Sugawara K et al (2017) Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: possible roles in scleroderma. J Exp Med 214:1129\u20131151","journal-title":"J Exp Med"},{"key":"1786_CR45","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3899\/jrheum.110755","volume":"39","author":"T Taniguchi","year":"2012","unstructured":"Taniguchi T, Asano Y, Akamata K et al (2012) Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. J Rheumatol 39:539\u2013544","journal-title":"J Rheumatol"},{"key":"1786_CR46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/art.38948","volume":"67","author":"T Taniguchi","year":"2015","unstructured":"Taniguchi T, Asano Y, Akamata K et al (2015) Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice. Arthritis Rheumatol 67:517\u2013526","journal-title":"Arthritis Rheumatol"},{"key":"1786_CR47","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Hoogen van den","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:2737\u20132747","journal-title":"Arthritis Rheum"},{"key":"1786_CR48","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F Hoogen van den","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747\u20131755","journal-title":"Ann Rheum Dis"},{"key":"1786_CR49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2741\/s22","volume":"1","author":"J Varga","year":"2009","unstructured":"Varga J, Whitfield ML (2009) Transforming growth factor-\u03b2 in systemic sclerosis (scleroderma). Front Biosci (Schol Ed) 1:226\u2013235","journal-title":"Front Biosci (Schol Ed)"},{"key":"1786_CR50","first-page":"17","volume":"10","author":"JF Viallard","year":"1999","unstructured":"Viallard JF, Taupin JL, Miossec V, Pellegrin JL, Moreau BL (1999) Analysis of interleukin-6, interleukin-10 and leukemia inhibitory factor (LIF) production by peripheral blood cells from patients with systemic lupus erythematosus identifies LIF as a potential marker of disease activity. Eur Cytokine Netw 10:17\u201324","journal-title":"Eur Cytokine Netw"},{"key":"1786_CR51","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2353\/ajpath.2008.071049","volume":"172","author":"A Yoshizaki","year":"2008","unstructured":"Yoshizaki A, Iwata Y, Komura K et al (2008) CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 172:1650\u20131663","journal-title":"Am J Pathol"},{"key":"1786_CR52","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0016-5085(97)70175-6","volume":"113","author":"K Z\u2019Graggen","year":"1997","unstructured":"Z\u2019Graggen K, Walz A, Mazzucchelli L, Strieter RM, Mueller C (1997) The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease. Gastroenterology 113:808\u2013816","journal-title":"Gastroenterology"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00403-017-1786-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-017-1786-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-017-1786-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T06:19:58Z","timestamp":1693117198000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00403-017-1786-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1786"],"URL":"https:\/\/doi.org\/10.1007\/s00403-017-1786-4","relation":{},"ISSN":["0340-3696","1432-069X"],"issn-type":[{"value":"0340-3696","type":"print"},{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,16]]}}}